Blue Earth Diagnostics Reports Favorable Head‑to‑Head Study Results Comparing POSLUMA® (Flotufolastat F 18) and Piflufolastat F 18 for Assessing Urinary Bladder Radioactivity in Men with Biochemical Recurrent Prostate Cancer
“This rigorous head-to-head study provides high-quality evidence that POSLUMA has significantly lower urinary bladder radioactivity compared to piflufolastat F 18, confirming prior studies,” said Phillip Kuo, Kuo Radiology LLC. “POSLUMA also exhibited higher detection rates for recurrence compared to piflufolastat F 18, which highlights its potential to improve patient management.”